

#### **Registries and Research Infrastructures** Council of European Federations – 29 Oct 2013

Anna Kole, MPH – Registry and Biobanks Project Manager


#### **Comprehensive Definition of Registry**

A patient registry is an **organized system** that uses observational study methods to **collect uniform data** (clinical and other) to evaluate specified outcomes for **a population** defined by a particular disease, condition, or exposure, and that serves a predetermined scientific, clinical, or policy purpose(s). The registry database is the file (or files) derived from the registry.

US Agency for Healthcare Research and Quality's (AHRQ) - Registries for Evaluating Patient Outcomes: A User's Guide



#### **Registries in the Past**



#### **Registries Today**

 Perception of registries has changed for scientists, industry, policy makers and patients

 Now key solutions to pulling geographically and structurally dispersed information together



#### Value of Registries

- Creating a registry of patients is the single most valuable action a rare disease community can take. The registry provides critical disease knowledge which makes that disease easier to study, increasing the probability a treatment can be developed.- David Meeker, President and CEO of Genzyme, a Sanofi company.
- Research requires a community of interested-parties to reach the critical mass. Registries, European networks and patient organisations are determinants of research and development for rare diseases. Segolene Ayme, Orphanet, RDD 2009 European Workshop
- Registries are an indispensible infrastructure tool for translating basic and clinical research into improved care and therapeutic solutions. – Paola Coggi, DG Sanco, Dominique Ristori, JRC, European Commission
- The importance of rare disease registries cannot be underestimated. Our patient-led register was instrumental in triggering a national enquiry into the cause of death of patients... - patient organisation representative



#### **European Commission Committment**



04/11/2013











#### **European Recommendations**



**5 JUNE 2013** 

# European Platform for Rare Disease Registries

- European Commission has announced strategic objective in creating a European Platform on Rare Diseases Registration at Joint Research Center (JRC) in Ispra, Italy
- Common services and tools for the existing (and future) rare disease registries in Europe.
- 2M EUR over 3 years





#### JOINT RESEARCH CENTRE

Institute for Health and Consumer Protection (IHCP)



### European Platform for Rare Disease Registries

- In the framework of the EPIRARE project
- EURORDIS has proposed policy scenarios on the aims, scope, governance structure and long-term sustainability
  - Aims harmonise rare diseaes patient registries in Europe
  - Scope all RD all EU
  - Governance sound, with patient representation
  - Sustainability long term... beyond initial funding

#### Half a Score

#### An EPIRARE project production. Written and directed by Gianni Del Corral




# RD Connect


The genomic revolution will offer additional opportunities for improving health for patients with RD through advancing research and integrating data from – omics research with phenotypic information (patient registries) and biomaterials (biobanks).

-Hanns Lochmuller and Kate Bushby, Institute of Human Genetics, Newcastle University

#### **RD-Connect**


 a unique global infrastructure project that links up databases, registries, biobanks and clinical bioinformatics data used in rare disease research into a central resource for researchers worldwide





#### With time...

 More projects, more infrastructures... getting us closer to IRDIRC goals





#### **RD** Connect Project Objectives

- Harmonisation and development of common standards for databases and patient registries for rare (WP2)
- Harmonisation and development of common standards and a common catalogue for rare disease biobanks (WP3)
- Development of data mining and knowledge discovery tools for analysis and integration of molecular and clinical data to discover new disease genes, pathways and therapeutic targets (WP4)

#### **RD** Connect Project Objectives (2)

- Development of an integrated platform to host the processed data from Neuromics, EuRenOmics and future IRDiRC projects (WP5)
- Development of best ethical practices by engaging with relevant stakeholders including a proposal for an expedient regulatory framework for linking of medical and personal data related to rare disease on a European and global level (WP6)
- Ensuring access to project results and broad and global impact in science, diagnostics and translational research including industrial collaborations (WP7)

## **RD- Connect Who's Who?**



Anna Kole, Registry & Biobank Projects Manager, EURORIDS



Yann Le Cam, Chief Executive Officer, EURORDIS

WP2 WP3 WP5 WP6 WP7

WP3

WP4

WP5

WP6

WP7

WP2



Lucia Monaco, Chief Scientific Officer, Fondazione Telethon

Hanns Lochmüller, RD-Connect

Professor of Exp. Myology, Newcastle Univ. Chair of the IRDIRC Interdisciplinary Committee

Domenica Taruscio, Istituto Superiore

Coordinator

di Sanità



Christophe Béroud, Head of bioinformatics team at the UMR\_S 910 research unit, Aix-Marseille Univ. Medical School



**Ivo Gut,** Director of Centro Nacional de Análisis Genómico



Mats Hanson, Professor of Biomedical Ethics, Uppsala University



Kate Bushby, Professor of Neuromuscular Genetics, Newcastle Univ. , Co-chair of EUCERD



eurordis.org

WP1

#### Patient representation

- PATIENT INVOLVEMENT = IMPROVED RESEARCH PROGRESS
  - Dynamic dialogue between researchers and patients
  - Inter-understanding increases uptake and acceptance of technologies
  - Researchers know developments are relevant and needed
- Promotes high professional standards and ethical integrity
- Patient representatives as actors, ambassadors and governors builds confidence and trust



eurordis.org

#### EURORDIS – Specific Aims

- 1. Capacity building on registries, biobanks and -omics
- 2. Consulting patient perspective
- 3. Educational materials for project partners
- 4. Identifying sustainability models for long-term maintenance of registries
- 5. Encouraging increased participation in biobanks
- 6. Reporting on the impact of project activities
- 7. Ensure a strong interaction and coordination of the RD-CONNECT network with other initiatives within and beyond Europe
- 8. Dissemination of the RD-CONNECT project outcomes at the international level

ETHICAL, LEGAL, SOCIAL ISSUES

RESEARCH INFRASTRUCTURE BUILDING WP2 and 3


WP6

IMPACT AND EVALUATION

WP7



#### Ethical, Legal and Social Issues



eurordis.org

## Patients Advisory Council (PAC)

- Voluntary, informal EURORDS Working Group collecting different patient views on issues surrounding registries, biobanking and –omics research
- Advise the RD-Connect Governing Board and the coordinator from the patient perspective
- Initially covering diseases in EuRenOmics and NeurOmics projects, but now extended to others to include diversity in geographic scope and disease characteristics



## PAC Who's Who?



Muriel Gevrey, French Charcot Marie Tooth Association

60

Joseph Irwin, Jennifer Trust for Spinal Muscular Atrophy



Julian Isla, Dravet Syndrome Foundation



Sigurdur Johannesson, Alternating Hemiplegia of Childhood Federation of Europe



Anna Kole, EURORIDS



Dorthe Lykke, European Federation of Hereditary Spastic Paraplegia



Francisco Monfort, European Alliance of patients with Atypical Hemolytic Uremic Syndrome



Kay Parkinson, Alstrom Syndrome UK



Marita Pohlschmidt, Muscular Dystrphy Campaign



Daniel Renault, Federation of European Associations of Patients affected by Renal Genetic Diseases



Françoise Rouault, French Muscular Dystrophy Association - Téléthon

Balthasar Schaap, European Federation of Neurological Associations/EuroAtaxia



Juliette Senecat, EURORDIS



Inge Schwersenz, Spinal Muscular Atrophy Europe



Chris Sotirelis, Spinal Muscular Atrophy Europe



Oliver Timmis, The Alkaptonuria Society



Mariek Van Meel, NephcEurope



Elizabeth Vroom, United Parent Projects Muscular Dystrophy



## **Capacity Building**

#### Workshops alongside project meetings

- Joint Annual Meetings (Sitges, Heidelberg) PROJECT AIMS
- IRDIRC Conference (Dublin) GLOBAL RARE DISEASE STRATEGY
- Stakeholder Conference on Regulatory Hurdles (Brussels) INFORMED CONSENT, DATA PROTECTION AND THE IMPORTANCE OF DATA SHARING
- European Conference for Rare Diseases (Berlin) PROJECT OUTCOMES, ENCOURAGING PARTICIPATION
- EURORDIS Summer School (Barcelona) FOUNDATON FOR THERAPEUTIC DEVELOPMENT
- EURORDIS Training module
- Advocacy materials
  - Factsheets
  - Online training
- Regular Updates
  - RD Connect website and newsletter
  - EURORDIS newsletter
  - EURORDIS membership events



### **Consulting Patient Perspective**

- Patient Advisory Council (EURORDIS Working Group)
- Literature Review
- Workshops
- Surveys
- Delphi exercise
- Participation in RD Connect, EURenOmics, NeurOmics and Joint Patient and Ethics Council
- Ad-hoc consultations

#### Get involved

04/11/2013

- Opportunity to involve patient voice in a new era of rare disease research where expectations of stakeholders is not fully mature.
- Join EURORDIS Working Group
- Share your experience and expectations and learn from the project outcomes